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Bone metastases occur in patients with advanced-stage prostate cancer (PCa). The cell-cell interaction between PCa and the bone
microenvironment forms a vicious cycle that modulates the bone microenvironment, increases bone deformities, and drives tumor
growth in the bone. However, the molecular mechanisms of PCa-mediated modulation of the bone microenvironment are complex
and remain poorly deﬁned. Here, we evaluated growth differentiation factor-15 (GDF15) function using in vivo preclinical PCa-bone
metastasis mouse models and an in vitro bone cell coculture system. Our results suggest that PCa-secreted GDF15 promotes bone
metastases and induces bone microarchitectural alterations in a preclinical xenograft model. Mechanistic studies revealed that
GDF15 increases osteoblast function and facilitates the growth of PCa in bone by activating osteoclastogenesis through
osteoblastic production of CCL2 and RANKL and recruitment of osteomacs. Altogether, our ﬁndings demonstrate the critical role of
GDF15 in the modulation of the bone microenvironment and subsequent development of PCa bone metastasis.
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INTRODUCTION
Prostate cancer (PCa), the most common malignant tumor in men,
is the second leading cause of cancer deaths in males worldwide1.
Patients with advanced PCa frequently exhibit distant metastasis,
with bone being the preferential site in nearly 90% of metastatic
PCa patients2. Skeletal metastasis is one of the leading causes of
mortality in PCa patients3. Although the 5-year survival rate of
advanced PCa patients without bone metastasis is nearly 60%, it
substantially decreases to 3% in the presence of bone metastases3,4. PCa bone metastasis is accompanied by skeletalassociated complications such as hypercalcemia, intense pain in
the bone, bone fractures, and spinal cord compression5. The
treatment options for PCa-bone metastasis mostly focus on tumor
growth and management of pain; hence, the most advanced
disease remains incurable.
Bone is an extremely a dynamic organ that undergoes
continuous remodeling6. The bone microenvironment comprises osteoclasts and osteoblasts that function to resorb and
mineralize (form new) bone, respectively. The activities of these
two cell populations are tightly coupled to balance bone
turnover. Osteoblasts and osteoclasts originate from mesenchymal and hematopoietic stem cells, respectively6. The bone
microenvironment regularly secretes factors for bone maintenance that inadvertently provide a fertile environment for the
establishment and growth of tumors within the bone, leading to
a vicious cycle7. On the basis of radiological appearance, bone
metastatic lesions can be classiﬁed as osteolytic, osteoblastic, or

mixed. Bone metastases in PCa are osteoblastic in nature,
characterized by the net formation of new bone of poor
mechanical quality but featuring high levels of markers of bone
resorption/osteoclast activity8.
Transforming growth factor-β (TGF-β) is well known to support
PCa bone metastases9,10. Growth differentiation factor-15
(GDF15), also known as MIC-1, is a member of the TGF-β/bone
morphogenic protein superfamily. Physiologically, GDF15 has a
major role in prenatal development; the regulation of growth,
cartilage and bone formation; and cellular responses to
inﬂammation and stress11. In adults, GDF15 facilitates tissue
repair after acute injuries. GDF15, which is overexpressed in
various malignancies, including PCa, is a potential serum marker
in different types of cancers and contributes to tumor development and metastasis11–16. High serum GDF15 levels have been
observed in patients with bone metastasis17. Glial-derived
neurotrophic factor receptor alpha-like (GFRAL) was recently
identiﬁed as a receptor for GDF1518–21. GFRAL binds to the
coreceptor RET (a tyrosine-protein kinase) after binding with
GDF1518–21. GFRAL expression seems to be primarily conﬁned to
the central nervous system and mediates the anorectic effects of
GDF1522. However, the presence and role of this GDF15/GFRAL/
RET axis in PCa progression and bone metastasis remain obscure.
Here, we provide preclinical and clinical evidence to establish the
role of PCa-secreted GDF15 in bone metastasis and reveal the
mechanism underlying GDF15-mediated osteomac recruitment
and alteration of the bone microenvironment.
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RESULTS
GDF15 promotes PCa bone metastasis
To determine the clinical signiﬁcance of GDF15 expression, six
Oncomine datasets were evaluated. These datasets showed that
GDF15 is overexpressed in PCa patients compared to healthy
subjects (Fig. S1a). We further analyzed the TCGA database for
GDF15 expression and observed signiﬁcant upregulation of GDF15
in PCa patients and further increased GDF15 expression in
metastatic PCa patients (Fig. S1b and S1c). Next, we examined
GDF15 expression in a PCa tissue microarray (TMA), which showed
higher staining of GDF15 in prostate adenocarcinoma than in
normal prostate samples and increased expression with disease
progression (Fig. S1d). We found similar increases in the
expression of GDF15 at both the protein and mRNA levels in a
panel of human PCa cells compared to normal immortalized
RWPE1 cells (Fig. 1a and b).
Previously, we showed that overexpression of GDF15 enhances
the proliferation, migration, and anchorage-independent growth
of PCa cells23. The PC3 cell line, which has low GDF15 expression,
was used as a model to evaluate the functional role of GDF15 in
PCa bone metastasis. PC3 cell lines stably expressing doxycyclineinducible GDF15-luciferase or control vector-luciferase (PC3GDF15-Luc[i] or PC3-Luc[i]) were generated (Fig. 1c) and injected
intracardially into male nude mice. Metastatic lesions were
visualized via IVIS imaging (Fig. 1d). As shown by ex vivo
bioluminescent imaging, PCa cells overexpressing GDF15 exhibited widespread skeletal metastasis (in the hind limbs, forelimbs,
spinal cord, and ribs with sternum) after one month of inoculation
compared to that of control PC3-Luc(i) cells (Fig. 1e). Mice
inoculated with PC3-GDF15(i) cells showed declines in their body
weight, while those injected with PC3-Luc(i) cells did not (Fig. S1e).
After decalciﬁcation, the excised tibiae were processed and
examined for histopathological changes and metastatic lesions.
H&E staining of tibial sections showed tumor-induced cortical
bone deterioration in PC3-GDF15(i)-injected mice (Fig. 1f). Next,
we stained the bone sections with tartrate-resistant acid
phosphatase (TRAP) to determine the bone resorption capacity
of mice with PCa overexpressing GDF15. PC3-GDF15(i)-injected
mice exhibited more TRAP-positive cells (osteoclasts) and staining
with cathepsin K (a marker of functional osteoclasts) than PC3-Luc
(i)-implanted mice (Fig. 1f). PC3-GDF15(i)-injected mice also
showed more Ki67 staining than PC3-Luc(i) mice (Fig. 1f). To
examine the involvement of GDF15 in PCa-mediated bone
turnover, we measured serum P1NP and CTX levels, which reﬂect
the degree of bone formation and bone resorption, respectively.
PC3-GDF15(i)-injected mice exhibited signiﬁcantly higher serum
CTX and P1NP than PC3-Luc(i)-injected mice (Fig. 1g). Together,
these ﬁndings strongly suggest that GDF15 overexpression in PCa
cells promotes skeletal metastasis.
PCa-GDF15 modulates the bone microenvironment and favors
tumor growth in bone
To deﬁne the role of GDF15 in PCa-mediated modulation
of the bone microenvironment, we next generated PCa cell lines
(LNCaP C-81 and C4-2B) with GDF15 knockout (KO) using the
CRISPR–Cas9 system. Western blot analysis conﬁrmed the
complete knockout of GDF15 in LNCaP C-81 and C4-2B cell lines
(Fig. 2a). C4-2B (parental and GDF15 KO) PCa cells were inoculated
into the tibiae of nude mice. Higher bone destruction was seen in
C4-2B-injected tibiae than in PBS control-injected tibiae; however,
the deletion of GDF15 prevented bone destruction from PCa, as
shown by 3D reconstruction of images obtained from the highresolution µ-CT analysis of trabecular bone (Fig. 2b). Next, we
examined alterations in bone mineral density (BMD) in the tibiae
of animals injected with PBS, C4-2B, and C4-2B (GDF15 KO) cells.
The BMD was signiﬁcantly lower in C4-2B cell-injected tibiae than
in contralateral nontumor control tibiae; however, deletion of
GDF15 did not decrease BMD (Fig. 2b). C4-2B-injected mice

showed visible destruction of trabecular bone, while tibiae
obtained from the C4-2B (GDF15 KO)-injected mice were
comparable to those of PBS-injected control mice (Fig. S2a, Video
1 & Video 2).
We quantiﬁed PCa-mediated trabecular deterioration of the
tibial epiphyses (sites of the intratibial injections) of C4-2B and C42B (GDF15 KO) cell-injected mice at the architectural level by µ-CT
analysis. C4-2B-injected mice had signiﬁcant microarchitectural
deterioration, as indicated by reduced bone trabecular volume
(BV/TV), trabecular thickness (Tb.Th), connection density (reﬂecting trabecular connectedness), and trabecular number (Tb.N), and
increased trabecular separation (Tb.S). Deletion of GDF15 in C4-2B
cells improved bone microarchitectural parameters, such as BV/TV,
Tb.Th, connection density, Tb.N and Tb.S, compared to the
parameters in GDF15-deﬁcient mice (Figs. 2c and S2b). Furthermore, IHC analysis of the decalciﬁed tibial sections revealed that
tumors formed from C4-2B (GDF15 KO) cells had a lower
proliferative index than tumors formed from C4-2B cells, as
indicated by fewer Ki67‐positive cells (Fig. 2d). The deletion of
GDF15 in C4-2B cells also decreased osteoclast formation and
function, as reﬂected by reduced TRAP and cathepsin-K staining
(Fig. 2e). Serum analysis of bone turnover markers demonstrated
that CTX and P1NP levels were signiﬁcantly increased in the C42B-injected mice compared to the age-matched healthy control
mice. In contrast, C4-2B (GDF15 KO)-injected mice showed
signiﬁcantly lower serum CTX and P1NP levels than the C4-2Binjected group (Fig. 2f). Furthermore, we examined the expression
of mouse-speciﬁc GDF15 in the tibiae of C4-2B- and C4-2B (GDF15
KO)-injected mice. Interestingly, no signiﬁcant changes were
observed in mouse GDF15 expression in the bone of C4-2B PCainjected mice compared to that of PBS-injected or GDF15 KO cellinjected mice (Fig. S2c). Taken together, these ﬁndings indicate
that silencing GDF15 impairs tumor growth and progression while
protecting the bone microenvironment.
GDF15 increases the recruitment of bone macrophages
(osteomacs) via CCL2
Bone-resident macrophages, also known as osteomacs, play roles
in coordinating normal bone homeostasis and injury healing24.
Osteomacs have been shown to impact bone metastasis and PCa
progression in bone via osteoclast and osteoblast function25.
Chemokines, particularly C-C family members, affect the development and progression of PCa within the bone microenvironment by modulating the function of bone cells and facilitating the
recruitment of macrophages26,27. To determine whether GDF15
regulates the expression of C-C chemokines in bone cells, we
assessed the mRNA expression of C-C chemokines (CCL2, CCL3,
CCL7, and CCL12) in osteoblasts following treatment with either
rhGDF15 or conditioned medium (CM) collected from different
PCa cells. We found that CCL2 was highly expressed among
the analyzed chemokines in osteoblasts treated with rhGDF15
(Figs. 3a and S3a-S3c); CCL2 is well known for macrophage
recruitment and PCa growth in the bone microenvironment26–29.
Similarly, CM from PC3 cells overexpressing GDF15 signiﬁcantly
enhanced CCL2 expression in osteoblasts (Fig. 3b). In contrast, the
increase in CCL2 levels was smaller upon treatment with CM from
C4-2B (GDF15 KO) cells than upon treatment with CM from C4-2B
parental cells. However, C4-2B (GDF15 KO) cell-derived CM
supplemented with rhGDF15 induced CCL2 expression to levels
comparable to those of parental cells (Fig. 3b). Similar results
were observed with CM of the LNCaP C-81 cell line (Fig. S3d).
Immunohistochemistry showed signiﬁcantly higher CCL2 staining
in C4-2B-injected tibiae than in either PBS-injected control or C42B (GDF15 KO)-injected tibiae (Fig. 3c). In addition, lower serum
CCL2 levels were observed in mice injected with GDF15 KO PCa
cells than in mice injected with parental PCa cells (Fig. 3d). Mice
inoculated with PC3-GDF15(i) cells showed higher serum CCL2
levels than PC3-Luc(i)-injected mice (Fig. 3e). These data suggest
Bone Research (2022)10:6
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that PCa-secreted GDF15 profoundly increases CCL2 expression
in osteoblasts.
CCL2 plays a role in macrophage recruitment and fusion30. A
high degree of inﬁltration of F4/80− and CD68-positive
macrophages was observed in C4-2B-injected tibiae compared
to contralateral control tibiae. However, the inﬁltration of F4/80−
and CD68-positive macrophages in C4-2B (GDF15 KO)-injected
tibiae was lower than that in tibiae implanted with parental cells
and control tibiae (Fig. 3f). Together, these ﬁndings suggest that
PCa-secreted GDF15 regulates the expression of CCL2, which in
turn serves as a chemoattractant that guides osteomacs to the
bone surface.
PCa-secreted GDF15 augments mouse calvarial osteoblast (MCO)
activity
The communication between cancer cells and the bone microenvironment leads to a vicious cycle that induces bone
deformities and favors tumor growth in bone. Osteoblasts are
the primary bone-forming cells, and PCa patients show high
osteoblastic activity. Therefore, we investigated the effect of
PCa-secreted GDF15 on MCO differentiation. MCOs were cultured
in medium supplemented with increasing concentrations of
rhGDF15 or varying proportions of CM from PCa cells (20%,
40%, and 80% in αMEM) under osteoblast-differentiating conditions (in the presence of ascorbic acid and β-glycerophosphate)
for 48 h. Treatment with increasing concentrations of CM from
cells with high GDF15 (LNCaP C-81 & C4-2B) proportionally
increased MCO differentiation after 48 h, as assessed by alkaline
phosphatase (Fig. 4a). rhGDF15 also augmented MCO differentiation with increasing concentrations (Fig. 4b and c). Similarly, CM
from PC3 cells (which express low endogenous levels of GDF15)
engineered to overexpress GDF15 induced greater MCO differentiation than CM from parental cells (Fig. 4d). Next, CM obtained
from PCa cells (LNCaP C-81 & C4-2B) with GDF15 deletion
inhibited PCa-mediated osteoblast differentiation, and supplementation with rhGDF15 restored osteoblast differentiation
(Fig. 4e). These results suggest that GDF15 is crucial for PCa cells
to stimulate osteoblast differentiation. We also determined the
effect of PCa-secreted GDF15 on osteoblast mineralization, as
differentiated MCOs are capable of mineralizing bone matrix. MCO
cultures treated with rhGDF15 or CM from LNCaP C-81 and C4-2B
cells exhibited robust mineralization, as evidenced by alizarin redS-stained calciﬁed nodules, and this effect was abrogated upon
GDF15 knockdown (Fig. 4f). Gene expression analysis revealed
increased mRNA levels of the early osteogenic genes alkaline
phosphatase and Runx2 and the late osteogenic genes Col1a1 and
osteocalcin in osteoblasts treated with the CM of PCa cells
compared to the control (Fig. 4g). The increased expression of
PCa-mediated osteogenic genes was abrogated by GDF15 KO and
was partially restored by exogenous supplementation with
rhGDF15 (Fig. 4g), suggesting that some aspects of the stimulation
of osteoblast differentiation by PCa require GDF15.
Colony-forming unit ﬁbroblasts (CFU-Fs) are recognized as
early osteoblastic cell precursors, and the CFU-F assay is an
appropriate way to enumerate BMSCs in the bone marrow. To
assess the effect of GDF15 on the differentiation of BMSCs into
osteoblasts, mouse-derived BMSCs were cultured in bone
marrow differentiation medium for 10 and 21 days with and
without rhGDF15 or CM from PCa cells. rhGDF15 enhanced the
differentiation of BMSCs into osteoblasts and promoted mineralization, as assessed by alkaline phosphatase and alizarin red
staining (Fig. S4a and S4b). The CM from GDF15-null C4-2B and
LNCaP C-81 cells led to a decrease in BMSC differentiation
compared to that of their parental cells, but this effect was
reversed by supplementation with rhGDF15 (Fig. S4c). Similarly,
PCa-secreted GDF15 increased the mineralization of BMSCs, as
indicated by alizarin red-S staining (Fig. S4d). Together, these
data suggest that GDF15 contributes to the ability of PCa cells to

modulate osteoblastogenic functions, such as differentiation and
mineralization.
PCa-secreted GDF15 induces osteoclastogenesis
Since GDF15 deﬁciency in PCa cells dramatically reduced TRAP
staining (indicating the osteoclast number) in the bone microenvironment, we examined whether GDF15 released by PCa cells
might control osteoclast (OC) formation. We used bone marrow
from 4-week-old C57BL/6 J mice to generate OCs. Bone marrow
macrophages (BMMs) from mice were cultured in the presence of
M-CSF and RANKL with and without GDF15 for 7 days to stimulate
in vitro OC formation. The addition of rhGDF15 resulted in a
signiﬁcant increase in the number of TRAP-positive multinucleated
cells (Fig. 5a). Furthermore, we performed RT–qPCR analysis for
genes associated with the osteoclastogenesis of BMMs.
Osteoclast-speciﬁc genes such as TRAP, cathepsin K, NFATc1, and
carbonic anhydrase were elevated after 7 days of rhGDF15
treatment in the presence of M-CSF and RANKL (Fig. 5b). Since
our data suggest that PCa-secreted GDF15 increases C-C
chemokine (especially CCL2 and CCL12) expression in osteoblasts,
we next sought to examine the effect of CCL2 and CCL12 silencing
on GDF15-mediated osteoclastogenesis. CCL12 inhibition had no
effect, while CCL2 silencing signiﬁcantly inhibited the GDF15mediated increase in TRAP mRNA expression in cultured BMMs
(Figs. 5c and S5a and b). Similarly, treatment of BMMs with a
mouse-speciﬁc anti-CCL2 antibody inhibited the GDF15-mediated
upregulation of TRAP expression (Fig. 5d). Similar osteoclastogenic
effects were observed following the treatment of BMMs with CM
from C4-2B and LNCaP C-81 cells. These effects were abrogated
following the deletion of GFD15 and restored upon supplementation of CM with rhGDF15 (Fig. 5e). Together, these data suggest
that PCa-secreted GDF15 enhances RANKL-mediated osteoclast
differentiation and promotes bone resorption.
GDF15 increases the osteoclastogenic potential of osteoblasts via
an increased RANKL signal
Osteoblasts secrete RANK/receptor activator of NF-kappaB ligand
(RANKL) and osteoprotegerin (OPG), which are known to inﬂuence
osteoclast formation and function6. A healthy skeleton depends
on a balanced ratio of RANKL and OPG. Treatment with rhGDF15
resulted in the upregulation of RANKL in MCOs, but no effect was
observed on OPG expression (Fig. 6a). We next determined
whether GDF15 contributes to the PCa-mediated upregulation of
RANKL expression in osteoblasts. Treatment of MCOs with CM
from PCa cells (C4-2B and LNCaP C-81) led to increased
osteoblastic RANKL expression. However, treatment with CM from
GDF15-KO PCa cells signiﬁcantly decreased RANKL expression in
MCOs compared to that achieved with parental PCa cell lines, and
exogenous supplementation with rhGDF15 rescued RANKL
expression in MCOs (Figs. 6b and S6a). Although CM from
parental PCa cells (C4-2B and LNCaP C-81) did not alter
osteoblastic OPG expression, it did increase the RANKL/OPG ratio
compared to that achieved with CM from GDF15-KO PCa cells in
the bone microenvironment, reﬂecting increased resorption and
decreased bone mass (Fig. 6b and S6a).
Furthermore, we examined the expression of RANKL and OPG
in the tibiae of C4-2B- and C4-2B (GDF15 KO)-injected mice.
Interestingly, RANKL expression was higher in the bone of C4-2B
PCa-injected mice than in that of PBS-injected or C4-2B (GDF15
KO)-injected mice (Fig. S6b). Similar to the in vitro observations
with MCOs, the expression of OPG was not signiﬁcantly altered
in tibiae injected with C4-2B (GDF15 KO) vs. control tibiae;
however, the RANKL/OPG ratio was lower in the tibiae injected
with GDF15 KO cells than in those injected with parental cells
(Fig. S6b). These results suggest that GDF15 from PCa cells
mediates osteoclast formation and bone resorption by modulating the RANKL/OPG system. Furthermore, high alkaline phosphatase levels and osteocalcin-positive cells were observed in
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Fig. 4 PCa-secreted GDF15 augments osteogenic activity. a PCa factors promote osteoblast differentiation, as measured by alkaline phosphatase
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(after 48 h of treatment) and subjected to alkaline phosphatase activity analysis. b Treatment with rhGDF15 for 48 h increased osteoblast
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the tibiae from C4-2B-injected mice compared to the tibiae from
C4-2B GDF15 KO-injected mice, suggesting that the increase in
RANKL expression is due to GDF15-mediated osteoblast
differentiation. (Fig. 6c)

Recent reports have indicated that GFRAL and RET act as a
receptor and coreceptor of GDF15, respectively18–21; however, the
presence and role of these receptors in bone cells have not yet
been reported. IHC analysis showed that GFRAL and RET were
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present on the tibial sections of PC3-injected mice (Fig. 6d).
Furthermore, we validated GFRAL staining by in situ hybridization in
the isolated tibiae of mice using an RNA scope probe (Fig. S6c).
MCOs expressed both GFRAL and RET, along with Runx2 (Fig. 6e).
To understand the mechanism of downstream signaling of GDF15/
GFRAL, we knocked down GFRAL in MCOs and observed that
silencing GFRAL decreased the phosphorylation of AKTS473 and
ERKT202/Y204 (Fig. 6f). Furthermore, inhibition of GFRAL suppressed
the rhGDF15-mediated enhancement of ALP, RANKL, and CCL2
mRNA expression (Fig. 6g). Together, these results suggest that the
GDF15 receptor is present on osteoblastic precursors and might
regulate the observed effect of GDF15 on bone cells.
DISCUSSION
PCa patients frequently develop bone metastasis, which is a
major cause of morbidity and mortality. The fate of disseminated
PCa is mostly determined by the interaction of tumor cells and
the microenvironment of the metastatic niche. Unfortunately,
the biology of PCa bone metastasis remains poorly deﬁned.
Therefore, it is critical to understand the mechanism of PCamediated bone metastasis and identify PCa-secreted mediators
for therapeutic target identiﬁcation and effective treatment
development. Previously, we showed that GDF15 is highly
expressed in PCa cell lines, especially in the androgenindependent LNCaP-C81 cell line and its metastatic variant
LNCaP-Ln3, compared to the androgen-sensitive LNCaP-C33 cell
line15. In contrast, GDF15 levels are low or undetectable in
androgen-independent PC3 and DU145 PCa cells15. In accordance with published studies, we observed higher GDF15
expression in prostatic adenocarcinomas than in normal prostate
tissues, and the expression increased with disease stage31.
Similarly, high GDF15 was observed in bone metastasis specimens from PCa patients, and downregulation of GDF15 has been
shown to improve the cytotoxic effect of docetaxel31,32. These
ﬁndings raise the possibility that PCa-secreted GDF15 can
regulate bone remodeling in metastatic bone lesions.
A recent report showed that PCa induced the secretion of
GDF15 from terminally differentiated osteocytes, which stimulated
PCa growth and invasion by stimulating early growth response 1
(EGR1) expression in PCa cells and subsequently driving the
vicious cycle of bone metastasis33. However, the effects of PCasecreted GDF15 in the bone microenvironment were not
examined. Our study demonstrates the role of PCa-secreted
GDF15 in bone metastasis and modulation of bone cell function
and the microenvironment.
Our ﬁndings demonstrate that overexpression of GDF15
augments PCa metastasis to bone. It is well known that PC3 cells
increase their osteolytic activity when metastasizing to bone34. We
observed that overexpression of GDF15 increases PCa-mediated
osteoclast formation and activity, as indicated by high TRAP and
cathepsin K staining in bone. PCa patients with high serum levels
of P1NP and CTX have signiﬁcantly lower survival rates than
patients with normal levels of these bone biomarkers35. We found
increased serum levels of PINP and CTX with overexpression of
GDF15 in PCa cells, which predicted the appearance of skeletalrelated events, as seen in PCa patients with bone metastasis.
We observed that the GDF15-null PCa cell lines (C4-2B and
LNCaP-C81) exhibited a profoundly reduced ability to grow in the
bone microenvironment. Although PCa characteristically forms
osteoblastic lesions when it metastasizes to bone, the PCa-secreted
factors that regulate osteoclastogenesis remain unclear. C4-2B cells
have been reported to induce a mix of osteoblastic and osteolytic
lesions within the bone microenvironment36. Another report has
shown that tibiae injected with C4-2B cells do not show a change
in BMD compared with that of normal tibiae37. In line with other
previous studies, we observed that bone from C4-2B-injected
mice exhibited a decreased BMD and trabecular volume38,39.

We analyzed all bone parameters through µCT and found that
GDF15 is necessary for the PCa-mediated deterioration of
trabecular bone. It is well established that bone resorption is a
prerequisite for establishing PCa in the bone microenvironment,
although the mechanism and relationship to the osteoblastic
component remain unclear. Once cancer cells metastasize to bone,
the interaction and cross-communication between PCa cells and
the bone microenvironment result in a ‘vicious cycle,’ which leads
to bone destruction and the growth and survival of cancer cells40.
Cathepsin K-deﬁcient mice exhibit defective bone resorption,
which establishes cathepsin K as a marker of functional
osteoclasts41,42. Our studies demonstrate that PCa-GDF15 modulates cathepsin K expression in the bone microenvironment.
These in vivo ﬁndings strongly signify the role of GDF15 in PCainduced osteoclast formation, which provides a niche for the
growth of PCa.
Chemokines recruit macrophages and monocytes (precursors
of osteoclasts), inﬂuencing them toward active bone remodeling
for bone matrix resorption. We found that GDF15 increases the
levels of C-C family chemokines, including monocyte chemoattractant protein-1 (MCP-1/CCL2), a potent chemotactic factor for
monocytes in the bone microenvironment43. Osteoblastic CCL2
mediates both the catabolic and anabolic action of parathyroid
hormones43,44. Several lines of evidence suggest that autocrine
and paracrine functions of CCL2 are required for PCa growth and
invasion, and inhibition of CCR2 reduces CCL2-mediated PCa
growth and invasion45,46. Multiple studies have suggested that
CCL2 is responsible for macrophage recruitment and PCa
growth in the bone microenvironment26–29. CCL2 promotes
macrophage fusion, as demonstrated by the reduced ability of
recruited macrophages to form foreign body giant cells in CCL2null mice30. Recently, it has been shown that a distinct
population of bone-resident F4/80+ macrophages, termed
osteomacs, reside on the endosteal surface and modulate
osteoblast activity in normal bone remodeling as well as
following injury or damage to the bone47. These osteomacs
build canopy-like structures around osteoblasts engaged in
active remodeling47,48. Osteomacs are distinct from osteoclasts
and express common macrophage markers such as F4/80 and
CD68, but not TRAP49. We found that compared to GDF15-null
PCa cells, PCa cells expressing GDF15 increased the numbers of
F4/80+ macrophages within mouse tibiae. CD68 is a member of
the lysosome-associated membrane protein family and is
required for the normal morphology and function of osteoclasts,
and CD68−/− mice show impaired osteoclast activity (bone
resorption) and increased bone mass50. Mouse tibiae injected
with GDF15-deleted PCa cells showed fewer CD68+ macrophages in the bone microenvironment. These results suggest
that the deletion of GDF15 impaired the ability of PCa to recruit
osteomacs and stimulate osteoclast formation. Our ﬁndings
demonstrate that GDF15 is essential for PCa cells to recruit
monocytes/macrophages and that it promotes osteoclast
function in bone, probably via the upregulation of CCL2.
GDF15 has been shown to promote or inhibit osteoclast or
osteoblast differentiation51, depending on the study52,53. Wakchoure et al. found that GDF15 induces osteoclast activation and
osteoblast differentiation in bone marrow cells isolated from the
long bones of 10–12-week-old C57BL/6 J mice52. Another study
has reported that GDF15 promotes osteoclast differentiation and
inhibits osteoblast differentiation of peripheral blood mononuclear cells and human bone marrow-derived mesenchymal
stem cells51. This observed discrepancy might be due to the use of
different cells for osteoblast differentiation. The role of GDF15 in
these bone cells is not very clear. Thus, we isolated preosteoblasts
from neonatal mouse calvaria and found that GDF15 increased the
differentiation and mineralization of osteoblasts. In addition,
GDF15 promoted the osteogenic differentiation of bone marrow
stromal cells in a heterogeneous culture that contained
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monocytes and macrophages. These results suggest that PCasecreted GDF15 has osteogenic activity, which facilitates cancer
cell proliferation in the bone microenvironment.
In the bone microenvironment, osteoblasts control the development of osteoclasts from macrophages and preosteoclasts by
releasing RANKL and the decoy receptor OPG. RANKL binds to its
receptor RANK present on macrophages and preosteoclasts and
is necessary for osteoclast formation. Altered expression of RANKL
and OPG causes an imbalance between bone formation and
resorption, leading to osteolytic bone metastasis in PCa54. We
found for the ﬁrst time that GDF15 signiﬁcantly increased the
RANKL/OPG ratio (an indicator of bone resorption) in osteoblasts.
These results demonstrate an additional indirect role of GDF15 in
osteoclastogenesis via the RANKL/OPG axis. GDF15 also contributed to the loss of bone microarchitecture, speciﬁcally
trabecular bone, and enhanced bone resorption induced by
PCa. Notably, it has been reported recently that glial-derived
neurotrophic factor receptor alpha-like (GFRAL) acts as a receptor
of GDF1518–21. Before GFRAL was identiﬁed as a receptor of
GDF15, TGF-β receptor types I and II and intracellular SMAD signal
transduction protein complexes were thought to mediate the
cellular responses of GDF1555–57. In addition, GDF15 promotes
actin cytoskeleton rearrangement through activation of FAKRhoA-GEF-mediated signaling; however, the molecular mechanism is unclear23. GFRAL, upon binding with GDF15, interacts with
the RET receptor to initiate downstream signaling, such as
phosphorylation of ERK and AKT. However, the presence and role
of the GDF15/GFRAL/RET axis in PCa progression and metastasis
have not yet been reported.
GDF15 secreted from osteocytes promotes PCa growth and
invasion, and the presence of GFRAL on PCa cell lines has been
reported33. In the present study, we demonstrated the expression
of GFRAL and RET receptors on bone. The ERK and AKT pathways
are highly expressed in osteoblasts and promote their differentiation58–62. GFRAL silencing suggests that GDF15/GFRAL signaling
can regulate the differentiation of MCOs by activating the ERK and
AKT signaling pathways. Furthermore, silencing GFRAL reduces

the GDF15-mediated upregulation of osteoblastic RANKL and
CCL2 expression. It is likely that GDF15 binds to and activates
GFRAL and RET receptors present on bone cells. However, many
questions remain about the role and function of GFRAL and RET
receptor signaling in the bone microenvironment, which needs
further investigation. In light of these observations, it will be of
interest to investigate GFRAL and RET receptor signaling in the
context of the cancer-induced bone microenvironment and
microarchitectural remodeling, and targeting the GDF15/GFRAL/
RET axis could potentially provide a therapeutic avenue for
reducing PCa-mediated bone metastasis.
Elevated serum GDF15 has been correlated with increased
bone metastasis17. It will be interesting to examine whether
circulating GDF15 and GDF15 produced locally in the bone
microenvironment by tumor or stromal cells play similar or
distinct roles in promoting PCa bone metastasis. While it will be
of interest to utilize genetically engineered models with GDF15
or the receptors knock out in tumors or stromal compartments,
currently available prostate cancer models do not spontaneously
metastasize to bone at high frequency. Although TGF-β plays a
paradoxical role in tumor development, recent studies have
suggested that TGF-β signaling is essential for the development
of bone metastasis, and TGF-β-directed therapies inhibit prostate
cancer bone metastases63–65. In contrast, GDF15 is a divergent
member of the TGF-β superfamily with low sequence conservation with other members of the TGF superfamily66, and its
signaling through a recently identiﬁed novel receptor suggests
its unique role in PCa bone metastasis.
In conclusion, our ﬁndings suggest that PCa cells secrete GDF15,
which modulates bone marrow stromal cells (primarily osteoblasts). Osteoblasts, in turn, secrete RANKL and CCL2 to promote
osteoclastogenesis and bone deterioration, favoring the growth of
metastatic PCa tumor cells in the bone microenvironment (Fig. 7).
Overall, these data, combined with our previously published
ﬁndings, suggest that GDF15 plays a role in PCa bone metastases
through bone microenvironment modulation. It will be of interest
to determine the potential of targeting the GDF15/GFRAL/RET axis
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Fig. 7 Overall mode of action of PCa-secreted GDF15 on bone metastasis. GDF15 secreted from PCa modulates the activity of bone marrow
stromal cells through GFRAL/RET signaling. The GDF15-mediated increase in osteoblastic CCL2 production recruits osteomacs (bone
macrophages) toward bone and causes osteolysis of bone to create a metastatic niche for PCa cells in the bone microenvironment. In
addition, GDF15 also primes osteoblasts to produce high levels of RANKL that favor the growth of PCa cells in bone
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as a therapeutic strategy to prevent bone metastasis and increase
the quality of life of PCa patients.
MATERIALS AND METHODS
Animal use and ethics
All in vivo experiments were performed as per the University of
Nebraska Medical Center (UNMC) guidelines. Immunocompromised male athymic nude mice were generated and maintained
under a breeding and experimental protocol approved by the
UNMC Institutional Animal Care and Use Committee (IACUC), as
described previously67.
Cell line maintenance and preparation of conditioned media from
PCa cells
Human PCa cell lines (RWPE1, DU145, and PC3) were originally
obtained from the ATCC (Rockville, MD, USA), maintained in a CO2
incubator at 37 °C and routinely tested for STR proﬁles and
mycoplasma contamination. The culture conditions of RWPE1,
LNCaP C-81, and C42B PCa cells were as described in our earlier
publications68,69. For conditioned medium (CM) preparation,
LNCaP C-81, C42B, and PC3 cells (2 × 106) were grown overnight
in 100 mm culture dishes in cell culture medium. After two washes
with phosphate-buffered saline (PBS), the cells were incubated for
48 h in 1% FBS in RPMI medium before collection of the CM.
GDF15 inducible system
GDF15 was overexpressed in the PC3 cell line by using a 3rd
generation lentiviral system. We performed dual transduction
using rtTA along with a pLV[Tet]-mCherry:T2A:Puro>TRE3G >
FLAG/hGDF15/HA:T2A:Luciferase or pLV[Tet]-mCherry:T2A:Puro>TRE3G- > Luciferase vector obtained from VectorBuilder, TX, both
of which also expressed mCherry and luciferase (for quantitation
and in vivo imaging). For lentiviral transduction, PC3 cells (1 × 105)
were seeded in six-well plates. The lentiviral mixture (1 mL) and
8 μg·mL−1 polybrene were added to each well. After overnight
incubation, the transduction medium was replaced with fresh
RPMI medium. Transduction efﬁciency was assessed by visualizing
the cells for mCherry ﬂuorescence, and the positive cells were
sorted with a FACS Aria II (BD Biosciences). They were
subsequently transduced with rtTA-containing lentivirus to
activate TRE3G via the transactivator Tet3G.
Intracardiac injections of PCa
Intracardiac injections were performed to assess skeletal metastasis, as previously described70. Brieﬂy, PC-3-Luc(i) or PC3 GDF15(i)
cells (1 × 105) were injected into the left ventricles of male athymic
nude mice (4–6 weeks old). After the intracardiac injections,
the mice were kept on special water (doxycycline, 3.2 g·L−1, and
sucrose 30 g·L−1) to induce GDF15 overexpression. The
doxycycline-sucrose solution was changed every 3 to 4 days
throughout the experiment. Skeletal metastases were monitored
by bioluminescence detection of luciferase-expressing cells with
the IVIS system. Bones from all major skeletal sites were harvested
within 10 min after luciferin injection (150 mg·kg−1, i.p. injection)
and analyzed for bone metastasis via bioluminescence imaging.
The tibiae and femora were ﬁxed in 10% formalin for immunohistochemistry (IHC) and then decalciﬁed in 10% EDTA. Serum was
obtained from the collected blood after cardiac puncture at the
time of sacriﬁce to analyze the bone-related markers.
Intratibial injections of PCa
To study the effect of GDF15 deletion on tumor growth, athymic
nude male mice (4–6 weeks) were inoculated intratibially with C4-2B
and C4-2B (GDF15 KO) cells. Brieﬂy, mice were anesthetized with
ketamine and xylazine, and both legs were cleaned with 70%
ethanol. Luciferase-labeled PCa cell (C4-2B and C4-2B [GDF15 KO])
suspensions (5 × 106 cells in 20 µL) were injected into the proximal

part of the tibia using a syringe ﬁtted with a 27 3/8-inch gauge
needle. The other tibia was injected with an equal amount of PBS.
Bioluminescence imaging and radiography were used to assess the
tumor burden in the bone. All animals were sacriﬁced, and blood
and bone were collected for analyses of bone markers and histology.
Micro-computed tomography (μCT) analysis of mouse tibiae
After intratibial injection, μCT analysis of excised tibiae was
performed using a Sky Scan 1172 µCT scanner (Sky Scan, Ltd.,
Belgium). The tibiae were dissected from the mice after euthanasia
and cleaned of soft tissue. The samples were scanned at a nominal
resolution (pixels) of 9.7 µm. NRECON (Skyscan) was used for the
reconstruction of all images. Brieﬂy, the reconstructed data were
binarized using a threshold of 79–255. All three-dimensional
volumetric analyses of trabecular bone were accomplished using
CTAn software (Skyscan). The bone mineral density of trabecular
bone was calculated from the binary data based on a calibration
curve of calcium hydroxyapatite standards. To maintain consistency in tibial injection sites, we omitted the ﬁrst 50 slices from the
growth plate, after which another 258 slices were selected to
analyze the data. The μCT measurements followed the guidelines
of Bouxsein et al.71. Three-dimensional analyses were used to
determine the trabecular bone architecture72.
Western blot analysis
Cells were lysed with radioimmunoprecipitation assay (RIPA)
buffer containing protease and phosphatase inhibitors the
Lysates were freeze-thawed, syringe passaged, centrifuged at
23 000 r·min−1 for 25 min at 4 °C, subjected to sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis, and immunoblotted. Primary antibodies against GDF15 (Abcam); GFRAL
(Thermo Fisher Scientiﬁc); pERK, pAKT, ERK and AKT (Cell Signaling
Technology); and β-Actin (Sigma–Aldrich) were used for immunoblotting. The membranes were probed with the respective
secondary antibodies for an hour before the expression was
captured with enhanced chemiluminescence reagent as previously described73.
Culture of calvarial osteoblasts from mice
Mouse calvarial osteoblasts (MCOs) were obtained using a
previously published protocol of sequential digestion74. Brieﬂy,
calvaria from 1- to 2-day-old C57BL/6 J mice (5/6 of both sexes)
were pooled after sacriﬁce by decapitation. After isolation from
the skull using a midline incision, the calvaria were subjected to
ﬁve sequential (10–15 min) enzymatic digestions at 37 °C in a
solution containing 0.1% dispase and 0.1% collagenase. The
released cells after enzymatic digestion (second to ﬁfth digestions) were collected, centrifuged, and plated in T-25 ﬂasks in αMEM containing 10% FBS and 1% penicillin/streptomycin
(complete growth medium).
Osteoblast differentiation
MCOs were cultured in α-MEM supplemented with 10% FBS, and
after reaching 80%–90% conﬂuency, the cells were seeded at a
density of 2 × 103 cells/well in 96-well plates. The cells were
treated with different concentrations of rhGDF15 and CM from
PCa cells for 48 h in osteoblast differentiation medium (a-MEM
supplemented with 5% FBS, 10 mmol·L−1 β-glycerophosphate,
and 50 mg·mL−1 ascorbic acid). Osteoblast differentiation was
assessed by determination of alkaline phosphatase (ALP) activity
in cells. ALP activity was measured using p-nitrophenyl phosphate
as a substrate and quantitated colorimetrically at 405 nm75.
Mineralization of calvarial osteoblasts
Calvarial osteoblasts cultured until they reached 80% conﬂuence
were trypsinized and plated in differentiation medium (25 000
cells/well in a 12-well plate) consisting of complete growth
medium with ascorbic acid and β-glycerophosphate. The
Bone Research (2022)10:6
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medium was changed every alternate day for up to 21 days. The
treatment group contained a medium similar to that of the
GDF15 group. After completion of the experiment, the cells were
washed with PBS and ﬁxed with 4% paraformaldehyde in PBS for
15 min. The cells were stained with 40 mmol·L−1 (pH 4.5) alizarin
red-S for 30 min and then washed with water74. Quantiﬁcation
of staining was performed by cetylpyridinium chloride (CPC)
extraction as previously described74.
Mineralization of bone marrow stromal cells (BMSCs)
BMSCs from 4- to 6-week-old male C57BL/6 J mice were isolated and
cultured according to a previously published protocol76. In brief, the
femora and tibiae were excised aseptically, cleaned of soft tissues,
and washed in culture medium. Bone marrow was ﬂushed out in
20 mL of α-MEM. The BMSCs were counted and plated (2 × 106 cells/
well) in 12-well plates in culture medium consisting of α-MEM
supplemented with 10% FBS, dexamethasone (10−7 mol·L−1),
ascorbic acid (50 mg·mL−1), and β-glycerophosphate (10 mmol·L−1)
in the presence or absence of CM from different PCa cells along with
rhGDF15 for 21 days. The old medium was replaced every 48 h. After
21 days, the attached cells were ﬁxed in 4% formaldehyde for
20 min at room temperature and rinsed once in PBS. After ﬁxation,
the plates were stained with 40 mmol·L−1 alizarin red-S, which stains
areas rich in nascent calcium74.
RNA interference (siRNA treatment)
siRNA-mediated knockdown of GFRAL was performed in MCOs.
Brieﬂy, the MCOs were transfected with either target siRNA
(SMARTPool, concentration 50 nmol·L−1) or control siRNA using
ON-TARGET PLUS siRNA reagents (Dharmacon, Illinois, USA) as per
the manufacturer’s instructions. The efﬁcacy of GFRAL knockdown
was assessed by western blot analysis after 48 h of transfection.
For CCL2 and CCL12 knockdown, mouse BMM cultures were
transfected as described above, and the cultures were continued
for another 5 days with RANKL and MCSF and with or without
rhGDF15 (10 ng·mL−1). At the end of the experiments, RNA was
isolated to determine the TRAP transcript level.
Osteoclast differentiation from mouse bone marrow macrophages
(BMMs)
Bone marrow cells were isolated from 4-week-old C57BL/6 J mice,
as described previously43. Brieﬂy, after epiphyses of the bone were
removed from the tibia and femur, the marrow cavity was ﬂushed
entirely with α-MEM using a sterile 25-gauge needle. Bone marrow
macrophages (BMMs) were cultured in α-MEM containing 10%
FBS. The cell cultures were incubated with macrophage colonystimulating factor (M-CSF) (30 ng·mL−1) and receptor activator of
NF-kappaB ligand (RANKL) (50 ng·mL−1) and exposed to various
treatments consisting of rhGDF15 (0–100 ng·mL−1) and/or 20%
CM from PCa cells. GDF15 was added at the start of the culture
and at every medium change (every 2 days). After 7 days, cells
were collected for mRNA analysis. Osteoclast differentiation was
measured by determining the number of cells that had been
positively stained by tartrate-resistant acid phosphatase (TRAP).
Osteoclasts were identiﬁed as TRAP-positive-stained multinuclear
cells (fused cells with 3+ nuclei) using light microscopy74.
TRAP staining
After osteoclast differentiation, cells were ﬁxed with 4% paraformaldehyde in PBS for 30 min at room temperature and stained for
TRAP with a Leukocyte Acid Phosphatase Kit (387-A; Sigma–Aldrich)
following the manufacturer’s instructions43.
RNA isolation and quantitative real-time PCR analysis
An RNA isolation kit (Qiagen) was used to isolate the total RNA
from different experiments. Total RNA (1 μg) was used for the
synthesis of cDNA using random hexamers and TaqMan® Reverse
Transcription Reagents. SYBR® Green Master Mix (Roche) was used
Bone Research (2022)10:6

for quantitative real-time PCR using a Bio–Rad instrument. The
relative mRNA expression of genes was calculated using a formula
reported previously73. β-Actin was used to normalize the
expression levels, and the data are presented as the fold changes
compared with the levels in the control samples. The details of all
primers used in this study are provided in Supplementary Table
S1. After PCR ampliﬁcation, 20 μL of the PCR product was
electrophoresed in a 2% agarose gel for conventional PCR
assessment.
Serum analyses for CCL2, CTX, and PINP
Blood samples were collected by cardiac puncture from the mice
after the in vivo experiment. Sera were collected by centrifugation of
blood samples at 5 000 r·min−1 for 10 min. Serum C-terminal
telopeptide of collagen (CTX), N-Terminal Propeptide Of Type I
Procollagen (P1NP) (Immunodiagnostic Systems Inc.) and CCL2
(Invitrogen) were measured by ELISA according to the manufacturer’s instructions.
Immunohistochemistry and histology
At the end of the in vivo experiments, the tibiae and femora were
harvested, placed in fresh 10% formalin, and decalciﬁed in 10%
EDTA before parafﬁn embedding. Specimens were sectioned
(5 μm) and stained with H&E and TRAP (to identify osteoclasts;
Acid Phosphatase Leukocyte Kit, Sigma). For IHC of human GDF15,
CCL2, ALP, Ki67 and cathepsin K (intratibial experiment), the
sections were incubated with primary antibodies overnight at 4 °C
and then with a secondary antibody for 30 min at room
temperature. An ABC Staining System (Vector Laboratories) was
used as described previously77. For CD68, F4/80, GFRAL, RET,
cathepsin K (intracardiac experiment) and osteocalcin IHC,
sections were incubated with primary antibodies overnight at
4 °C and then with a secondary antibody for 20 min. The sections
were counterstained with hematoxylin. These IHC experiments
were performed using a Histo-Mouse Max AEC Detection Kit
(Invitrogen)43. Mouse IgG (Jackson ImmunoResearch Laboratory)
was used as a negative control. A similar IHC protocol was
adopted for analysis of GDF15 expression in clinical samples. A
commercially available prostate tissue microarray (TMA, US
Biomax, Rockville) was immunostained with an anti-GDF15
antibody. Semiquantitative scoring ranging from 0-3 was
performed by multiplying the staining intensity and percentage
of positively scored cells, as reported previously67. Quantiﬁcation
of IHC staining was performed with ImageJ software43. Details of
the antibodies used for immunohistochemistry are listed in
Supplementary Table S2.
RNA in situ hybridization assay
For in situ hybridization (ISH) of GFRAL, we used a commercially
available single-color mouse-speciﬁc 20-pair double-Z oligonucleotide probe (NM_205844.3, target region 2-1186) (Advanced
Cell Diagnostics). Brieﬂy, 5-μm decalciﬁed tibia sections from mice
were used for ISH. The slides were baked for 1 h at 60 °C, and for
deparafﬁnization, the sections were treated with protease for
30 min at 40 °C. Preheated target probes (GFRAL) were hybridized
for 2 h at 40 °C, and then a series of signal ampliﬁcation and
washing steps were performed using a HybEZ Hybridization
System. The hybridization signals of the probes were detected by
sequential chromogenic reactions using brown chromogens. For
detection of GFRAL RNA transcripts, we used a commercially
available kit (in situ hybridization with RNAscope® 2.5 HD AssayBROWN, RNAscope®)78. Brightﬁeld images were acquired using a
40x objective.
Statistical analysis
Student’s t test or one-way ANOVA was applied to evaluate
differences using the GraphPad InStat software program (GraphPad Software, Inc.). P values < 0.05 were considered to indicate
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statistical signiﬁcance. All in vitro assays were repeated a
minimum of two times. For in vivo assays, n indicates the number
of samples from different mice.
Study approval
All animal experiments were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) of UNMC.
ACKNOWLEDGEMENTS
The authors thank Kavita Mallya for her technical help. The authors also acknowledge
the University of Nebraska Medical Center small animal imaging facility and tissue
science facility for their resources and service. We also would like to thank Jessica
Mercer for editing this manuscript. This work and the authors are, in part, supported by
grants from the National Institutes of Health (NIH) U01 CA185148, DOD W81XWH-18-10308 (SKB), DOD W81XWH-21-1-0640 (JAS), and R01 CA218545, R01 CA241752 (MWN).

AUTHOR CONTRIBUTIONS
JAS and SKB conceived the idea and designed the experiments. SKB supervised the
study. JAS performed the study and drafted the manuscript. SM developed
the GDF15 KO cell lines. PS, SM, RP, PK, RV, SC, and SKM helped in performing the
experiments. SML, MJ, KD, MWN, and SKB helped revise the manuscript and provided
scientiﬁc feedback. All authors read and approved the ﬁnal paper.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41413-021-00178-6.
Competing interests: SKB is one of the co-founders of Sanguine Diagnostics and
Therapeutics, Inc. The other authors declare no competing interests. The authors
have declared that the submitted manuscript is original and is not under
consideration by another journal. Every author is aware of and has agreed to the
content of this paper.

REFERENCES
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69,
7–34 (2019).
2. Sartor, O. & de Bono, J. S. Metastatic Prostate Cancer. N. Engl. J. Med. 378,
645–657 (2018).
3. Bubendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study of
1,589 patients. Hum. Pathol. 31, 578–583 (2000).
4. Norgaard, M. et al. Skeletal related events, bone metastasis and survival of
prostate cancer: a population based cohort study in Denmark (1999 to 2007). J.
Urol. 184, 162–167 (2010).
5. Tsuzuki, S., Park, S. H., Eber, M. R., Peters, C. M. & Shiozawa, Y. Skeletal complications in cancer patients with bone metastases. Int J. Urol. 23, 825–832 (2016).
6. Siddiqui, J. A. & Partridge, N. C. Physiological bone remodeling: systemic regulation and growth factor involvement. Physiol. (Bethesda) 31, 233–245 (2016).
7. Shupp A. B., Kolb A. D., Mukhopadhyay D., Bussard K. M. Cancer metastases to
bone: concepts, mechanisms, and interactions with bone osteoblasts. Cancers
(Basel) 10, (2018).
8. Saad, F., Eastham, J. A. & Smith, M. R. Biochemical markers of bone turnover and
clinical outcomes in men with prostate cancer. Urol. Oncol. 30, 369–378 (2012).
9. Fournier, P. G. et al. The TGF-beta signaling regulator PMEPA1 suppresses prostate cancer metastases to bone. Cancer Cell 27, 809–821 (2015).
10. Tu, W. H. et al. The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia 5, 267–277 (2003).
11. Mimeault, M. & Batra, S. K. Divergent molecular mechanisms underlying the
pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J. Cell Physiol. 224, 626–635 (2010).
12. Adela, R. & Banerjee, S. K. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J. Diabetes Res. 2015, 490842 (2015).
13. Vocka, M. et al. Growth/differentiation factor 15 (GDF-15) as new potential serum
marker in patients with metastatic colorectal cancer. Cancer Biomark. 21, 869–874
(2018).
14. Wang, Y., Jiang, T., Jiang, M. & Gu, S. Appraising growth differentiation factor 15
as a promising biomarker in digestive system tumors: a meta-analysis. BMC
Cancer 19, 177 (2019).
15. Karan, D. et al. Dysregulated expression of MIC-1/PDF in human prostate tumor
cells. Biochem. Biophys. Res. Commun. 305, 598–604 (2003).

16. Kaur, S. et al. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the
diagnosis of lethal pancreatic cancer. PLoS One 8, e55171 (2013).
17. Windrichova, J. et al. MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
Anticancer Res. 37, 1501–1505 (2017).
18. Emmerson, P. J. et al. The metabolic effects of GDF15 are mediated by the orphan
receptor GFRAL. Nat. Med. 23, 1215–1219 (2017).
19. Hsu, J. Y. et al. Non-homeostatic body weight regulation through a brainstemrestricted receptor for GDF15. Nature 550, 255–259 (2017).
20. Mullican, S. E. et al. GFRAL is the receptor for GDF15 and the ligand promotes
weight loss in mice and nonhuman primates. Nat. Med. 23, 1150–1157 (2017).
21. Yang, L. et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity
effects of the ligand. Nat. Med. 23, 1158–1166 (2017).
22. Tsai, V. W. et al. The anorectic actions of the TGFbeta cytokine MIC-1/GDF15
require an intact brainstem area postrema and nucleus of the solitary tract. PLoS
One 9, e100370 (2014).
23. Senapati, S. et al. Overexpression of macrophage inhibitory cytokine-1 induces
metastasis of human prostate cancer cells through the FAK-RhoA signaling
pathway. Oncogene 29, 1293–1302 (2010).
24. Lo, C. H. & Lynch, C. C. Multifaceted roles for macrophages in prostate cancer
skeletal metastasis. Front. Endocrinol. (Lausanne) 9, 247 (2018).
25. Wu, A. C. et al. CD169(+) macrophages mediate pathological formation of woven
bone in skeletal lesions of prostate cancer. J. Pathol. 239, 218–230 (2016).
26. Mizutani, K. et al. The chemokine CCL2 increases prostate tumor growth and
bone metastasis through macrophage and osteoclast recruitment. Neoplasia 11,
1235–1242 (2009).
27. Mulholland, B. S., Forwood, M. R. & Morrison, N. A. Monocyte Chemoattractant
Protein-1 (MCP-1/CCL2) drives activation of bone remodelling and skeletal
metastasis. Curr. Osteoporos. Rep. 17, 538–547 (2019).
28. Loberg, R. D. et al. CCL2 as an important mediator of prostate cancer growth in vivo
through the regulation of macrophage inﬁltration. Neoplasia 9, 556–562 (2007).
29. Roca, H. et al. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J.
Biol. Chem. 284, 34342–34354 (2009).
30. Kyriakides, T. R. et al. The CC chemokine ligand, CCL2/MCP1, participates in
macrophage fusion and foreign body giant cell formation. Am. J. Pathol. 165,
2157–2166 (2004).
31. Mimeault, M., Johansson, S. L. & Batra, S. K. Pathobiological implications of the
expression of EGFR, pAkt, NF-kappaB and MIC-1 in prostate cancer stem cells and
their progenies. PLoS One 7, e31919 (2012).
32. Mimeault, M., Johansson, S. L. & Batra, S. K. Marked improvement of cytotoxic
effects induced by docetaxel on highly metastatic and androgen-independent
prostate cancer cells by downregulating macrophage inhibitory cytokine-1. Br. J.
Cancer 108, 1079–1091 (2013).
33. Wang, W. et al. Prostate cancer promotes a vicious cycle of bone metastasis
progression through inducing osteocytes to secrete GDF15 that stimulates
prostate cancer growth and invasion. Oncogene 38, 4540–4559 (2019).
34. Tassone, E. et al. KLF4 as a rheostat of osteolysis and osteogenesis in prostate
tumors in the bone. Oncogene 38, 5766–5777 (2019).
35. Brasso, K. et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL40 in patients with metastatic prostate carcinoma. Prostate 66, 503–513 (2006).
36. Dai, J. et al. Cabozantinib inhibits prostate cancer growth and prevents tumorinduced bone lesions. Clin. Cancer Res. 20, 617–630 (2014).
37. Hall, C. L., Baﬁco, A., Dai, J., Aaronson, S. A. & Keller, E. T. Prostate cancer cells promote
osteoblastic bone metastases through Wnts. Cancer Res. 65, 7554–7560 (2005).
38. Morrissey, C., Kostenuik, P. L., Brown, L. G., Vessella, R. L. & Corey, E. Host-derived
RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft
model of experimental bone metastases. BMC Cancer 7, 148 (2007).
39. Pﬁtzenmaier, J. et al. Characterization of C4-2 prostate cancer bone metastases
and their response to castration. J. Bone Min. Res. 18, 1882–1888 (2003).
40. Guise, T. A. The vicious cycle of bone metastases. J. Musculoskelet. Neuronal
Interact. 2, 570–572 (2002).
41. Kiviranta, R. et al. Impaired bone resorption in cathepsin K-deﬁcient mice is partially compensated for by enhanced osteoclastogenesis and increased expression
of other proteases via an increased RANKL/OPG ratio. Bone 36, 159–172 (2005).
42. Li, C. Y. et al. Mice lacking cathepsin K maintain bone remodeling but develop
bone fragility despite high bone mass. J. Bone Min. Res. 21, 865–875 (2006).
43. Siddiqui, J. A. et al. Catabolic effects of human PTH (1-34) on bone: requirement
of monocyte chemoattractant protein-1 in murine model of hyperparathyroidism. Sci. Rep. 7, 15300 (2017).
44. Siddiqui, J. A. et al. Osteoblastic monocyte chemoattractant protein-1 (MCP-1)
mediation of parathyroid hormone’s anabolic actions in bone implicates TGFbeta signaling. Bone 143, 115762 (2021).
45. Lu, Y. et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and
autocrine factor for prostate cancer growth and invasion. Prostate 66, 1311–1318
(2006).

Bone Research (2022)10:6

Role of GDF15 in prostate cancer bone metastasis
JA Siddiqui et al.

15
46. Siddiqui, J. A. & Partridge, N. C. CCL2/Monocyte chemoattractant protein 1 and
parathyroid hormone action on bone. Front. Endocrinol. (Lausanne) 8, 49 (2017).
47. Winkler, I. G. et al. Bone marrow macrophages maintain hematopoietic stem cell
(HSC) niches and their depletion mobilizes HSCs. Blood 116, 4815–4828 (2010).
48. Chang, M. K. et al. Osteal tissue macrophages are intercalated throughout human
and mouse bone lining tissues and regulate osteoblast function in vitro and
in vivo. J. Immunol. 181, 1232–1244 (2008).
49. Sinder, B. P., Pettit, A. R. & McCauley, L. K. Macrophages: Their Emerging Roles in
Bone. J. Bone Min. Res. 30, 2140–2149 (2015).
50. Ashley, J. W. et al. Genetic ablation of CD68 results in mice with increased bone
and dysfunctional osteoclasts. PLoS One 6, e25838 (2011).
51. Westhrin, M. et al. Growth differentiation factor 15 (GDF15) promotes osteoclast
differentiation and inhibits osteoblast differentiation and high serum GDF15
levels are associated with multiple myeloma bone disease. Haematologica 100,
e511–e514 (2015).
52. Wakchoure, S. et al. Expression of macrophage inhibitory cytokine-1 in prostate
cancer bone metastases induces osteoclast activation and weight loss. Prostate
69, 652–661 (2009).
53. Vanhara, P. et al. Growth/differentiation factor-15 inhibits differentiation into
osteoclasts-a novel factor involved in control of osteoclast differentiation. Differentiation 78, 213–222 (2009).
54. Nakai, Y. et al. Efﬁcacy of an orally active small-molecule inhibitor of RANKL in
bone metastasis. Bone Res. 7, 1 (2019).
55. Johnen, H. et al. Tumor-induced anorexia and weight loss are mediated by the
TGF-beta superfamily cytokine MIC-1. Nat. Med. 13, 1333–1340 (2007).
56. Tan, M., Wang, Y., Guan, K. & Sun, Y. PTGF-beta, a type beta transforming growth
factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor
cell growth via TGF-beta signaling pathway. Proc. Natl. Acad. Sci. USA 97,
109–114 (2000).
57. Xu, J. et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor
released from the myocardium in association with SMAD protein activation. Circ.
Res. 98, 342–350 (2006).
58. Ge, C., Xiao, G., Jiang, D. & Franceschi, R. T. Critical role of the extracellular signalregulated kinase-MAPK pathway in osteoblast differentiation and skeletal
development. J. Cell Biol. 176, 709–718 (2007).
59. Xiao, G. et al. Bone morphogenetic proteins, extracellular matrix, and mitogenactivated protein kinase signaling pathways are required for osteoblast-speciﬁc
gene expression and differentiation in MC3T3-E1 cells. J. Bone Min. Res. 17,
101–110 (2002).
60. Xiao, G., Jiang, D., Gopalakrishnan, R. & Franceschi, R. T. Fibroblast growth factor 2
induction of the osteocalcin gene requires MAPK activity and phosphorylation of the
osteoblast transcription factor, Cbfa1/Runx2. J. Biol. Chem. 277, 36181–36187 (2002).
61. Xiao, G. et al. MAPK pathways activate and phosphorylate the osteoblast-speciﬁc
transcription factor, Cbfa1. J. Biol. Chem. 275, 4453–4459 (2000).
62. Mukherjee, A. & Rotwein, P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J. Cell Sci. 122, 716–726 (2009).
63. Juarez, P. & Guise, T. A. TGF-beta in cancer and bone: implications for treatment
of bone metastases. Bone 48, 23–29 (2011).
64. Hu, Z. et al. Systemic delivery of oncolytic adenoviruses targeting transforming
growth factor-beta inhibits established bone metastasis in a prostate cancer
mouse model. Hum. Gene Ther. 23, 871–882 (2012).

Bone Research (2022)10:6

65. Wan, X. et al. Effect of transforming growth factor beta (TGF-beta) receptor I
kinase inhibitor on prostate cancer bone growth. Bone 50, 695–703 (2012).
66. Bootcov, M. R. et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent
member of the TGF-beta superfamily. Proc. Natl. Acad. Sci. USA 94, 11514–11519
(1997).
67. Seshacharyulu, P. et al. FDPS cooperates with PTEN loss to promote prostate
cancer progression through modulation of small GTPases/AKT axis. Oncogene 38,
5265–5280 (2019).
68. Muniyan, S. et al. Sildenaﬁl potentiates the therapeutic efﬁcacy of docetaxel in
advanced prostate cancer by stimulating NO-cGMP signaling. Clin. Cancer Res. 26,
5720–5734 (2020).
69. Mimeault, M. et al. Inhibition of hedgehog signaling improves the anti-carcinogenic
effects of docetaxel in prostate cancer. Oncotarget 6, 3887–3903 (2015).
70. Park, S. I., Kim, S. J., McCauley, L. K. & Gallick, G. E. Pre-clinical mouse models of
human prostate cancer and their utility in drug discovery. Curr. Protoc. Pharm.
Chapter 14 14, 15 (2010).
71. Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents
using micro-computed tomography. J. Bone Min. Res. 25, 1468–1486 (2010).
72. Siddiqui, J. A. et al. A naturally occurring rare analog of quercetin promotes peak
bone mass achievement and exerts anabolic effect on osteoporotic bone.
Osteoporos. Int. 22, 3013–3027 (2011).
73. Pothuraju, R. et al. Molecular implications of MUC5AC-CD44 axis in colorectal
cancer progression and chemoresistance. Mol. Cancer 19, 37 (2020).
74. Siddiqui, J. A. et al. 8,8”-Biapigeninyl stimulates osteoblast functions and inhibits
osteoclast and adipocyte functions: Osteoprotective action of 8,8”-biapigeninyl in
ovariectomized mice. Mol. Cell Endocrinol. 323, 256–267 (2010).
75. Trivedi, R. et al. Kaempferol has osteogenic effect in ovariectomized adult
Sprague-Dawley rats. Mol. Cell Endocrinol. 289, 85–93 (2008).
76. Wang, Y. et al. BK ablation attenuates osteoblast bone formation via integrin
pathway. Cell Death Dis. 10, 738 (2019).
77. Vengoji, R. et al. Afatinib and Temozolomide combination inhibits tumorigenesis
by targeting EGFRvIII-cMet signaling in glioblastoma cells. J. Exp. Clin. Cancer Res.
38, 266 (2019).
78. Wang, F. et al. RNAscope: a novel in situ RNA analysis platform for formalin-ﬁxed,
parafﬁn-embedded tissues. J. Mol. Diagn. 14, 22–29 (2012).

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.

© The Author(s) 2022

